2.73 USD
▼-0.19-6.51%
盘后 3.12 0.00%
2026-09-15
市值
$308.21M
市盈率
—
EPS
-1.25
股息率
—
52 周区间
1.96 – 6.16
成交量
1.47M
Beta
1.80
目标价
12.29
52W 低 1.9652W 高 6.16
价格走势
公司简介
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2...